LINC00094/miR-19a-3p/CYP19A1 Axis Affects the Sensitivity of ER Positive Breast Cancer Cells to Letrozole Through EMT Pathway

Overview

Journal Aging (Albany NY)

Specialty Geriatrics

Date 2022 Jun 3

PMID 35657638

Authors

Yuan Xiang

Hui Liu

Hao Hu

Le-Wei Li

Qi-Bei Zong

Tang-Wei Wu

Xiao-Yi Li

Shi-Qiang Fang

Yi-Wen Liu

Yu Zhan

Hui Wang

Zhong-Xin Lu

Affiliations

Soon will be listed here.

Abstract

The endocrine therapy resistance of breast cancer is the difficulty and challenge to be urgently solved in the current treatment. In this study, we examined the effects of noncoding RNA LINC00094 and miR-19a-3p on breast cancer and by RT-QPCR, Western Blot, luciferase assay, immunofluorescence and drug sensitivity tests. The plasma level of CYP19A1 in patients with breast cancer resistance was lower than that in drug sensitive patients. Compared with normal subjects, miR-19a-3p was highly expressed in plasma of patients with breast cancer. miR-19a-3p is highly expressed in estrogen receptor positive breast cancer cells. The expression of miR-19a-3p promoted the migration and EMT of breast cancer cells and reduced the sensitivity of breast cancer to Letrozole. LINC00094 sponge adsorbed miR-19a-3p. LINC00094 promotes the expression of CYP19A1, the target gene of miR-19a-3p, and inhibits the EMT process of breast cancer, ultimately promoting the sensitivity of ER-positive breast cancer cells to Letrozole. This study found a new mechanism of Letrozole sensitivity in ER positive breast cancer.

Citing Articles

Metformin regulates the proliferation and motility of melanoma cells by modulating the LINC00094/miR-1270 axis.

Tsai K, Liao J, Tseng H Cancer Cell Int. 2024; 24(1):384.

PMID: 39563323 PMC: 11575040. DOI: 10.1186/s12935-024-03545-5.

CYP19A1 regulates chemoresistance in colorectal cancer through modulation of estrogen biosynthesis and mitochondrial function.

Wang Y, Ji Q, Cao N, Ge G, Li X, Liu X Cancer Metab. 2024; 12(1):33.

PMID: 39468645 PMC: 11520061. DOI: 10.1186/s40170-024-00360-4.

Quercetin inhibits the epithelial-mesenchymal transition and reverses CDK4/6 inhibitor resistance in breast cancer by regulating circHIAT1/miR-19a-3p/CADM2 axis.

Li X, Niu C, Yi G, Zhang Y, Jin W, Zhang Z PLoS One. 2024; 19(7):e0305612.

PMID: 38990915 PMC: 11239024. DOI: 10.1371/journal.pone.0305612.

Identification of immune-related regulatory networks and diagnostic biomarkers in thyroid eye disease.

Tong X, Shen Q Int Ophthalmol. 2024; 44(1):38.

PMID: 38332455 DOI: 10.1007/s10792-024-03017-9.

TFAP2C Activates CST1 Transcription to Facilitate Breast Cancer Progression and Suppress Ferroptosis.

Yuan L, Zhou D, Li W, Guan J, Li J, Xu B Biochem Genet. 2024; 62(5):3858-3875.

PMID: 38243003 DOI: 10.1007/s10528-023-10660-x.

References

Sang Y, Chen B, Song X, Li Y, Liang Y, Han D . circRNA_0025202 Regulates Tamoxifen Sensitivity and Tumor Progression via Regulating the miR-182-5p/FOXO3a Axis in Breast Cancer. Mol Ther. 2019; 27(9):1638-1652. PMC: 6731174. DOI: 10.1016/j.ymthe.2019.05.011. View

Kang H, Xiao X, Huang C, Yuan Y, Tang D, Dai X . Potent aromatase inhibitors and molecular mechanism of inhibitory action. Eur J Med Chem. 2017; 143:426-437. DOI: 10.1016/j.ejmech.2017.11.057. View

Hanker A, Sudhan D, Arteaga C . Overcoming Endocrine Resistance in Breast Cancer. Cancer Cell. 2020; 37(4):496-513. PMC: 7169993. DOI: 10.1016/j.ccell.2020.03.009. View

Xiang Y, Liao X, Yao A, Qin H, Fan L, Li J . MRTF-A-miR-206-WDR1 form feedback loop to regulate breast cancer cell migration. Exp Cell Res. 2017; 359(2):394-404. DOI: 10.1016/j.yexcr.2017.08.023. View

Wang Q, Peng L, Chen Y, Liao L, Chen J, Li M . Characterization of super-enhancer-associated functional lncRNAs acting as ceRNAs in ESCC. Mol Oncol. 2020; 14(9):2203-2230. PMC: 7463357. DOI: 10.1002/1878-0261.12726. View

Li J, Xiang Y, Fan L, Yao A, Li H, Liao X . Long noncoding RNA H19 competitively binds miR-93-5p to regulate STAT3 expression in breast cancer. J Cell Biochem. 2018; 120(3):3137-3148. DOI: 10.1002/jcb.27578. View

Razavi P, Chang M, Xu G, Bandlamudi C, Ross D, Vasan N . The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. Cancer Cell. 2018; 34(3):427-438.e6. PMC: 6327853. DOI: 10.1016/j.ccell.2018.08.008. View

Zhou Q, Zeng H, Ye P, Shi Y, Guo J, Long X . Differential microRNA profiles between fulvestrant-resistant and tamoxifen-resistant human breast cancer cells. Anticancer Drugs. 2018; 29(6):539-548. DOI: 10.1097/CAD.0000000000000623. View

Luengo-Gil G, Garcia-Martinez E, Chaves-Benito A, Conesa-Zamora P, Navarro-Manzano E, Gonzalez-Billalabeitia E . Clinical and biological impact of miR-18a expression in breast cancer after neoadjuvant chemotherapy. Cell Oncol (Dordr). 2019; 42(5):627-644. DOI: 10.1007/s13402-019-00450-2. View

10.

Liao X, Xiang Y, Yu C, Li J, Li H, Nie Q . STAT3 is required for MiR-17-5p-mediated sensitization to chemotherapy-induced apoptosis in breast cancer cells. Oncotarget. 2017; 8(9):15763-15774. PMC: 5362521. DOI: 10.18632/oncotarget.15000. View

11.

Yao A, Xiang Y, Si Y, Fan L, Li J, Li H . PKM2 promotes glucose metabolism through a let-7a-5p/Stat3/hnRNP-A1 regulatory feedback loop in breast cancer cells. J Cell Biochem. 2018; 120(4):6542-6554. DOI: 10.1002/jcb.27947. View

12.

Wa Q, Li L, Lin H, Peng X, Ren D, Huang Y . Downregulation of miR‑19a‑3p promotes invasion, migration and bone metastasis via activating TGF‑β signaling in prostate cancer. Oncol Rep. 2017; 39(1):81-90. PMC: 5783607. DOI: 10.3892/or.2017.6096. View

13.

Magnani L, Frige G, Gadaleta R, Corleone G, Fabris S, Kempe M . Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ERα metastatic breast cancer. Nat Genet. 2017; 49(3):444-450. PMC: 5326683. DOI: 10.1038/ng.3773. View

14.

Xie C, Liu S, Wu B, Zhao Y, Chen B, Guo J . miR-19 Promotes Cell Proliferation, Invasion, Migration, and EMT by Inhibiting SPRED2-mediated Autophagy in Osteosarcoma Cells. Cell Transplant. 2020; 29:963689720962460. PMC: 7784565. DOI: 10.1177/0963689720962460. View

15.

Liang Z, Li Y, Huang K, Wagar N, Shim H . Regulation of miR-19 to breast cancer chemoresistance through targeting PTEN. Pharm Res. 2011; 28(12):3091-100. DOI: 10.1007/s11095-011-0570-y. View

16.

Gansler T, Ganz P, Grant M, Greene F, Johnstone P, Mahoney M . Sixty years of CA: a cancer journal for clinicians. CA Cancer J Clin. 2010; 60(6):345-50. DOI: 10.3322/caac.20088. View

17.

Kim C, Oh J, Lee J, Kim M . The LncRNA HOTAIRM1 Promotes Tamoxifen Resistance by Mediating HOXA1 Expression in ER+ Breast Cancer Cells. J Cancer. 2020; 11(12):3416-3423. PMC: 7150441. DOI: 10.7150/jca.38728. View

18.

Soutschek J, Akinc A, Bramlage B, Charisse K, Constien R, Donoghue M . Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature. 2004; 432(7014):173-8. DOI: 10.1038/nature03121. View

19.

Li S, Sun X, Miao S, Liu J, Jiao W . Differential protein-coding gene and long noncoding RNA expression in smoking-related lung squamous cell carcinoma. Thorac Cancer. 2017; 8(6):672-681. PMC: 5668523. DOI: 10.1111/1759-7714.12510. View

20.

Gu J, Wang Y, Wang X, Zhou D, Shao C, Zhou M . RETRACTED: Downregulation of lncRNA GAS5 confers tamoxifen resistance by activating miR-222 in breast cancer. Cancer Lett. 2018; 434:1-10. DOI: 10.1016/j.canlet.2018.06.039. View